Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ALMS Alumis Inc

7,00

-0,69 (-8,97%)

11 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Alumis (NASDAQ:ALMS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Alumis Charts.

Alumis (NASDAQ:ALMS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Alumis Charts.

News Alumis Inc

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
Donnerstag 19 Dezember 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 8-K - Current report
Montag 25 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Donnerstag 14 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
Mittwoch 13 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Montag 4 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Freitag 27 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Alumis to Participate in Upcoming September Investor Conferences
Dienstag 3 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Dienstag 13 August 2024 (5 Monate vor) • GlobeNewswire Inc.

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
Montag 29 Juli 2024 (5 Monate vor) • GlobeNewswire Inc.

Alumis Announces Pricing of Initial Public Offering
Freitag 28 Juni 2024 (7 Monate vor) • GlobeNewswire Inc.

Weitere Alumis Inc News-Artikel

Invesco QQQ Trust Series 1

Energy Select Sector SPDR

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen